期刊
JOURNAL OF ASTHMA
卷 42, 期 1, 页码 65-71出版社
TAYLOR & FRANCIS LTD
DOI: 10.1081/JAS-200044748
关键词
asthma; bronchial provocation tests; phospholipases A; randomized controlled trials; spirometry
The possible roles of secretory phospholipases A(2) (sPLA(2)) in asthma include the release of arachidonic acid from cellular membranes, generation of lysophospholipids, sPLA(2)-mediated activation of cPLA(2) with increased leukotriene production, and surfactant degradation. LY333013 is a potent inhibitor of sPLA(2). This study examined the impact of two doses of LY333013 vs. placebo on allergen-induced bronchoconstriction following inhaled allergen challenge in atopic asthmatics. Fifty subjects were randomly assigned to treatment, and 40 subjects completed the study. A double-blind, placebo-controlled, random order, crossover study design was used. LY333013 had no impact on the primary outcome variables of the areas under the FEV1 response curve early (0-3 hours) (AUC(early)) and late (3-8 hours) (AUC(late)) following inhaled allergen challenge. No significant drug-related adverse effects were observed. The response to inhaled allergen challenge was reproducible and confirms the utility of this technique as a model in which to screen compounds for further testing in asthmatic patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据